A monoclonal antibody against human GPRC5D and its preparation method and use
Through mRNA immune technology, GPRC5D antibodies with natural conformations are generated in animals, which solves the antigen quality problem in the development of GPRC5D antibodies and achieves efficient multiple myeloma treatment, especially in recurrent patients with significant improvement in the treatment effect.
Patent Information
- Application Number
- CN202410741603.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-11
AI Technical Summary
It is difficult to develop effective GPRC5D antibodies in the prior art, especially because GPRC5D, as a multi-transmembrane protein, is complex in structure and difficult to maintain a natural conformation in traditional methods, resulting in antigen quality problems and affecting the treatment of recurrent patients with multiple myeloma.
Using mRNA immunologic technology to introduce mRNA encoding GPRC5D in animals, direct translation modification of intramuscular injection produces GPRC5D proteins with natural conformations, triggering immune responses and producing effective antibodies, including designing heavy and light chains with specific CDR sequences. Monoclonal antibodies in the variable region.
It has achieved high cell binding activity, low internalization efficiency, strong ADCC effect and specific binding. It is suitable for bispecific antibodies, CAR-T and classic antibodies, significantly improving the effect on the treatment of multiple myeloma.
Smart Images

Figure CN118324916B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a monoclonal antibody against human GPRC5D and a preparation method and use thereof. Background Art
[0002] GPRC5D (G protein-coupled receptor class C group 5 member D) is a C-type 7-channel transmembrane receptor protein, belonging to the G protein-coupled receptor family and a member of the GPRC5 subfamily. As an orphan receptor, GPRC5D is expressed at a low level in normal human tissues, usually only in hair follicle cells, but is specifically overexpressed in malignant plasma cells of multiple myeloma patients, and is closely related to the poor prognosis and overall survival rate of multiple myeloma patients.
[0003] Multiple myeloma (MM) originates from the malignant proliferation of plasma cells in the hematopoietic tissue of the bone marrow, leading to extensive bone destruction, osteopenia and pathological fractures. It is the second most common hematological malignancy after non-Hodgkin's lymphoma, with rapid disease progression, high recurrence rate and poor prognosis. The current treatment of multiple myeloma mainly uses CD38 monoclonal antibody combined with protease inhibitors, BCMA-targeted immunotherapy, immunomodulators and other methods. However, the problem of relapse after treatment of MM patients has not yet been solved, especially for patients with low or negative BCMA expression, the treatment effect is poor, and new targets are urgently needed to treat relapsed multiple myeloma. Studies in recent years have shown that GPRC5D plays an important role in the progression of MM disease and is an effective potential therapeutic target. In September 2023, Talvey, a CD3 / GPRC5D dual-antibody drug developed by Janssen, a subsidiary of Johnson & Johnson, has been accelerated by the US FDA for the treatment of adult patients with relapsed or refractory multiple myeloma. Developing GPRC5D antibody drugs to expand the market is an effective strategy for the treatment of multiple myeloma.
[0004] The development of therapeutic monoclonal antibody drugs is usually limited by the quality of immune antigens. GPRC5D is a multi-transmembrane protein with a complex structure. It is difficult to maintain its natural conformation by traditional expression and purification methods, and it is impossible to obtain effective antigens. This is also the biggest reason for the obstruction of GPCR antibody drug development. mRNA immunization technology can effectively solve this problem. Artificially synthesized mRNA encoding GPRC5D is introduced into the animal body by intramuscular injection. The mRNA entering the cytoplasm can be directly translated and correctly translated into a GPRC5D protein with a natural conformation in the mammalian body. No adjuvant is required, and effective antibodies are produced by causing a series of immune responses. Summary of the invention
[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a monoclonal antibody against human GPRC5D to solve the problems in the prior art.
[0006] To achieve the above objectives and other related objectives, the present invention provides an anti-GPRC5D antibody in a first aspect, wherein the anti-GPRC5D antibody comprises a heavy chain variable region and a light chain variable region, and the anti-GPRC5D antibody has the following characteristics:
[0007] 1) The heavy chain variable region includes CDR1 having an amino acid sequence as shown in SEQ ID NO.2;
[0008] 2) The heavy chain variable region includes CDR2 having an amino acid sequence as shown in SEQ ID NO.3;
[0009] 3) The heavy chain variable region includes CDR3 having an amino acid sequence as shown in SEQ ID NO.4;
[0010] 4) The light chain variable region includes CDR1 having an amino acid sequence as shown in SEQ ID NO.6;
[0011] 5) The light chain variable region includes a CDR2 with an amino acid sequence as shown in SEQ ID NO.7, wherein the amino acid sequence of the CDR2 is KVS;
[0012] 6) The light chain variable region includes CDR3 having an amino acid sequence as shown in SEQ ID NO.8.
[0013] In certain embodiments of the present invention, the anti-GPRC5D antibody comprises a heavy chain and a light chain. The heavy chain of the anti-GPRC5D antibody comprises the three heavy chain CDRs and a heavy chain framework region for connecting the heavy chain CDRs; and the light chain of the anti-GPRC5D antibody comprises the three light chain CDRs and a light chain framework region for connecting the light chain CDRs.
[0014] In certain embodiments of the present invention, the heavy chain variable region is a heavy chain variable region whose sequence is shown in SEQ ID NO.1.
[0015] In certain embodiments of the present invention, the heavy chain of the anti-GPRC5D antibody further comprises a heavy chain constant region.
[0016] In certain embodiments of the present invention, the heavy chain constant region of the anti-GPRC5D antibody is of human, mouse or rabbit origin, preferably human origin.
[0017] In certain embodiments of the present invention, the light chain variable region is a light chain variable region whose sequence is shown in SEQ ID NO.5.
[0018] In certain embodiments of the present invention, the light chain of the anti-GPRC5D antibody further comprises a light chain constant region.
[0019] In certain embodiments of the present invention, the light chain constant region of the anti-GPRC5D antibody is of human, mouse or rabbit origin, preferably human origin.
[0020] In certain embodiments of the present invention, the anti-GPRC5D antibody is a humanized antibody.
[0021] In certain embodiments of the invention, the anti-GPRC5D antibody specifically binds to GPRC5D.
[0022] In certain embodiments of the present invention, the anti-GPRC5D antibody is a double-chain antibody or a single-chain antibody.
[0023] In certain embodiments of the present invention, the anti-GPRC5D antibody is a monoclonal antibody.
[0024] In certain embodiments of the present invention, the antibody comprises a monospecific, bispecific, or trispecific antibody.
[0025] The second aspect of the present invention provides a recombinant protein, which comprises the anti-GPRC5D antibody as described in the first aspect of the present invention and an optional tag sequence for facilitating expression and / or purification.
[0026] The third aspect of the present invention is a CAR construct, the extracellular domain of the CAR construct contains the scFv of the anti-GPRC5D antibody as described in the first aspect of the present invention.
[0027] The fourth aspect of the present invention provides a recombinant immune cell, which expresses an exogenous CAR construct as described in the third aspect of the present invention.
[0028] In certain embodiments of the present invention, the immune cells are selected from the group consisting of NK cells and T cells.
[0029] In certain embodiments of the present invention, the immune cells are from humans or non-human mammals (such as mice).
[0030] The fifth aspect of the present invention provides an antibody conjugate, wherein the antibody-drug conjugate comprises:
[0031] 1) an antibody portion, wherein the antibody portion is selected from the group consisting of the antibody according to the first aspect of the present invention, or the recombinant protein according to the second aspect of the present invention, or a combination thereof; and
[0032] 2) A coupling portion coupled to the antibody portion, wherein the coupling portion is selected from one or more of the following: a detectable marker, a drug, a toxin, a cytokine, a radionuclide, and an enzyme.
[0033] In a sixth aspect of the present invention, there is provided a use of an active ingredient, wherein the active ingredient is selected from one or more of the following: the antibody as described in the first aspect of the present invention, the recombinant protein as described in the second aspect of the present invention, the CAR construct as described in the third aspect of the present invention, the immune cell as described in the fourth aspect of the present invention, and the antibody conjugate as described in the fifth aspect of the present invention, wherein the active ingredient is used for:
[0034] a) preparing a reagent or a kit for detecting GPRC5D protein;
[0035] b) Preparation of drugs or preparations for preventing and / or treating GPRC5D-related diseases.
[0036] In certain embodiments of the present invention, the GPRC5D-related disease is multiple myeloma.
[0037] In a seventh aspect of the present invention, a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises:
[0038] a) an active ingredient, wherein the active ingredient is selected from one or more of the following: the anti-GPRC5D antibody as described in the first aspect of the present invention, the recombinant protein as described in the second aspect of the present invention, the CAR construct as described in the third aspect of the present invention, the immune cell as described in the fourth aspect of the present invention, and the antibody conjugate as described in the fifth aspect of the present invention; and
[0039] b) a pharmaceutically acceptable carrier.
[0040] In a certain embodiment of the present invention, the pharmaceutical composition is a liquid preparation.
[0041] In a certain embodiment of the present invention, the pharmaceutical composition is an injection.
[0042] In a certain embodiment of the present invention, the pharmaceutical composition is used to treat tumors.
[0043] In a certain embodiment of the present invention, the tumor is a tumor that highly expresses GPRC5D.
[0044] The eighth aspect of the present invention provides an isolated polynucleotide encoding the anti-GPRC5D antibody as described in the first aspect of the present invention, the recombinant protein as described in the second aspect of the present invention, and the CAR construct as described in the third aspect of the present invention.
[0045] The ninth aspect of the present invention provides an expression vector comprising the isolated polynucleotide as described in the eighth aspect of the present invention.
[0046] In one embodiment of the present invention, the expression vector includes: bacterial plasmid, bacteriophage, yeast plasmid, plant cell virus, mammalian cell virus such as adenovirus, retrovirus, or other expression vectors.
[0047] The tenth aspect of the present invention provides a cell comprising the expression vector as described in the ninth aspect of the present invention or the isolated polynucleotide as described in the eighth aspect of the present invention integrated into its genome.
[0048] The eleventh aspect of the present invention provides a method for preparing the anti-GPRC5D antibody as described in the first aspect of the present invention, comprising culturing the cell as described in the tenth aspect of the present invention, and isolating the anti-GPRC5D antibody from the cell culture.
[0049] The twelfth aspect of the present invention provides a method for in vitro non-diagnostic detection (including diagnostic or non-diagnostic) of GPRC5D protein in a sample, the method comprising the steps of:
[0050] a) contacting the sample with the anti-GPRC5D antibody according to the first aspect of the present invention in vitro;
[0051] b) Detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of GPRC5D protein in the sample.
[0052] The thirteenth aspect of the present invention provides an in vitro method for detecting (including diagnostic or non-diagnostic) GPRC5D protein in a sample, the method comprising the steps of:
[0053] a) contacting the sample with the anti-GPRC5D antibody according to the first aspect of the present invention in vitro;
[0054] b) Detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of GPRC5D protein in the sample.
[0055] The fourteenth aspect of the present invention provides a method for treating a GPRC5D-related disease, the method comprising: administering to a subject in need thereof the antibody as described in the first aspect of the present invention, the antibody conjugate as described in the fifth aspect of the present invention, or a CAR-T cell expressing the anti-GPRC5D antibody, or a combination thereof.
[0056] As described above, the monoclonal antibody against human GPRC5D of the present invention has the following beneficial effects:
[0057] 1) Anti-GPRC5D antibodies have high cell binding activity;
[0058] 2) The internalization efficiency of anti-GPRC5D antibody is lower than that of Talquetamab, which is more conducive to the application of bispecific antibodies, CAR-T and classical antibodies;
[0059] 3) Anti-GPRC5D antibodies mediated a strong ADCC effect;
[0060] 4) Anti-GPRC5D antibody did not non-specifically bind to GPRC5A-positive cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 Shown are the variable region sequences of humanized anti-GPRC5D antibodies.
[0062] Figure 2 Shown are the humanized anti-GPRC5D antibody CDR sequences.
[0063] Figure 3 Shown are constant region amino acid sequences.
[0064] Figure 4 Shown are the results of the binding experiment between anti-GPRC5D antibody and CHOK1-hGPRC5D cells.
[0065] Figure 5 Shown are the results of internalization of anti-GPRC5D antibody on CHOK1-hGPRC5D cells.
[0066] Figure 6 The results are shown for ADCC effect mediated by anti-GPRC5D antibody.
[0067] Figure 7 Shown are the results of non-specific binding detection of anti-GPRC5D antibody. DETAILED DESCRIPTION
[0068] The term "antibody" refers to immunoglobulin, which is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the heavy chain of immunoglobulin are different, so its antigenicity is also different. Based on this, immunoglobulins can be divided into five categories, or different types of immunoglobulins, namely IgM, IgD, IgG, IgA and IgE. The heavy chain constant regions corresponding to different classes of immunoglobulins are called α, δ, ε, γ and μ respectively. IgG represents the most important class of immunoglobulins. Due to differences in chemical structure and biological function, it can be divided into 4 subclasses: IgG1, IgG2, IgG3 and IgG4. Light chains are divided into κ or λ chains due to differences in the constant region. The subunit structure and three-dimensional configuration of different classes of immunoglobulins are well known to people in the field.
[0069] The sequences of about 110 amino acids near the N-terminus of the heavy and light chains of antibodies vary greatly, which is the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region (C region). The variable region includes three hypervariable regions (HVRs) and four relatively conservative FR regions (FR). The amino acid sequences of the four FRs are relatively conservative and do not directly participate in the binding reaction. The three hypervariable regions determine the specificity of the antibody, also known as the complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) are composed of three CDR regions and four FR regions, arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from the amino terminus to the carboxyl terminus. The three CDR regions of the light chain, namely the light chain hypervariable regions (LCDRs), refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain, namely the heavy chain hypervariable regions (HCDRs), refer to HCDR1, HCDR2, and HCDR3. The number and position of the CDR amino acid residues in the LCVR and HCVR regions of the antibodies or antigen-binding fragments of the invention conform to the known Kabat numbering rules, or conform to the numbering rules of Kabat and Chothia. The four FR regions in the natural heavy and light chain variable regions are generally in a b-fold configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial b-fold structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain form the antigen binding site of the antibody. The amino acids that constitute the FR or CDR region can be determined by comparing the amino acid sequences of antibodies of the same type. The constant regions are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in the antibody-dependent cellular toxicity of antibodies.
[0070] A "complete" antibody is an antibody comprising an antigen-binding variable region and a light chain constant region (C) and heavy chain constant regions CH1, CH2 and CH3. The constant region may be a native sequence constant region (e.g., a human native sequence constant region) or an amino acid sequence variant thereof. Preferably, the complete antibody has one or more effector functions.
[0071] "Antibody fragments" comprise a portion of an intact antibody, preferably comprising its antigen binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2, Fv fragments, linear antibodies, and single chain antibodies (single chain Fv, scFv).
[0072] The "Fv" fragment is an antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of the variable region of a heavy chain and a variable region of a light chain tightly linked, and the connection (as in scFv) can be covalent. In this configuration, the three CDRs of each variable region interact to define the antigen binding site on the surface of the VH-VL dimer.
[0073] A "Fab" fragment includes the variable and constant regions of the light chain and the variable and first constant regions (CH1) of the heavy chain. A F(ab')2 antibody fragment comprises a pair of Fab fragments, which are usually covalently linked near their carboxyl termini by hinge cysteines between them. Other chemical coupling methods for antibody fragments are also known in the art.
[0074] "Single-chain antibody" or "scFv" antibody fragments comprise the VH and VL domains of an antibody. Typically, a single-chain antibody further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form an ideal structure for binding to an antigen.
[0075] The term "linear antibody" comprises a pair of tandem Fd segments (VH-CH1-VH-CH1), which together with complementary light chain polypeptides form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
[0076] "Antigenic determinant" refers to a discrete three-dimensional site on an antigen that is recognized by the antibodies or antigen-binding fragments of the invention.
[0077] The term "sequence identity" means the degree of identity between two nucleic acids or two amino acid sequences when optimally compared and compared with mutations such as appropriate substitutions, insertions or deletions. The sequence identity between the sequences described in the present invention and the sequences with identity thereof can be at least 85%, 90% or 95%, preferably at least 95%. Non-limiting examples include 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%.
[0078] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0079] In the present invention, antibodies include murine, chimeric, humanized or fully human antibodies prepared using techniques well known to those skilled in the art. Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, including human and non-human parts, can be prepared using DNA recombinant techniques well known in the art.
[0080] "Monoclonal antibody" refers to an antibody secreted by a clone from a single cell source. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. The cell may be a eukaryotic, prokaryotic, or phage clone.
[0081] "Chimeric antibodies" are antibody molecules that are spliced from the V region gene of a mouse antibody and the C region gene of a human antibody into a chimeric gene, which is then inserted into a vector and transfected into a host cell for expression. It retains the high specificity and affinity of the parent mouse antibody, and enables its human Fc segment to effectively mediate biological effect functions.
[0082] The "humanized" form of non-human (such as rodent) antibodies refers to a chimeric antibody that contains a sequence derived from a non-human immunoglobulin at a minimum. To a great extent, humanized antibodies refer to immunoglobulins in which the hypervariable region residues in human immunoglobulins (recipient antibodies) are replaced with hypervariable region residues of non-human species (donor antibodies) such as mice, rats, rabbits or non-human primates with the desired specificity, affinity and ability. In some cases, the framework region (FR) residues of human immunoglobulins are replaced with corresponding non-human residues. Moreover, humanized antibodies may be included in residues not found in the receptor antibody or the donor antibody. These modifications are made in order to further improve the performance of the antibody. Generally, humanized antibodies will contain substantially no less than at least one, usually two of the following variable regions, wherein all or substantially all of the hypervariable loops correspond to the hypervariable loops of non-human immunoglobulins, and all or substantially all of the FRs are FRs of human immunoglobulin sequences. Optionally, humanized antibodies will also contain at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin.
[0083] In the present invention, the antibody can be monospecific, bispecific, trispecific, or more multispecific. In one aspect, the present invention provides an anti-GPRC5D antibody, wherein the anti-GPRC5D antibody comprises a heavy chain variable region and a light chain variable region, and the anti-GPRC5D antibody has the following characteristics:
[0084] 1) The heavy chain variable region includes CDR1 having an amino acid sequence as shown in SEQ ID NO.2;
[0085] 2) The heavy chain variable region includes CDR2 having an amino acid sequence as shown in SEQ ID NO.3;
[0086] 3) The heavy chain variable region includes CDR3 having an amino acid sequence as shown in SEQ ID NO.4;
[0087] 4) The light chain variable region includes CDR1 having an amino acid sequence as shown in SEQ ID NO.6;
[0088] 5) The light chain variable region includes a CDR2 with an amino acid sequence as shown in SEQ ID NO.7, wherein the amino acid sequence of the CDR2 is KVS;
[0089] 6) The light chain variable region includes CDR3 having an amino acid sequence as shown in SEQ ID NO.8.
[0090] Among them, any of the above amino acid sequences also includes a derivative sequence with GPRC5D binding affinity after adding, deleting, modifying and / or replacing at least one (such as 1-5, 1-3, preferably 1-2, and more preferably 1) amino acid.
[0091] In certain embodiments of the present invention, the sequence formed by adding, deleting, modifying and / or replacing at least one amino acid sequence is preferably an amino acid sequence with a homology of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
[0092] The antibody of the present invention may be a double-chain or single-chain antibody, and may be selected from animal-derived antibodies, chimeric antibodies, and humanized antibodies, more preferably humanized antibodies, human-animal chimeric antibodies, and more preferably fully humanized antibodies.
[0093] The antibody derivatives of the present invention may be single-chain antibodies and / or antibody fragments, such as Fab, Fab', (Fab')2 or other antibody derivatives known in the art, as well as any one or more of IgA, IgD, IgE, IgG and IgM antibodies or other subtypes of antibodies.
[0094] Wherein, the animal is preferably a mammal, such as a mouse.
[0095] The antibody of the present invention can be a murine antibody, a chimeric antibody, a humanized antibody, a CDR-grafted and / or modified antibody targeting human GPRC5D. In certain embodiments of the present invention, any one or more of the above SEQ ID NOs. 2, 3, and 4, or sequences thereof having GPRC5D binding affinity after addition, deletion, modification and / or substitution of at least one amino acid, are located in the CDR region of the heavy chain variable region (VH).
[0096] In certain embodiments of the present invention, any one or more of the above SEQ ID NOs. 6, 7, 8, or sequences thereof having GPRC5D binding affinity after addition, deletion, modification and / or substitution of at least one amino acid, are located in the CDR region of the light chain variable region (VL).
[0097] In certain embodiments of the present invention, HCDR1, HCDR2, and HCDR3 are independently selected from any one or several sequences of SEQ ID NO. 2, 3, and 4, or sequences thereof having GPRC5D binding affinity after addition, deletion, modification, and / or substitution of at least one amino acid; LCDR1, LCDR2, and LCDR3 are independently selected from any one or several sequences of SEQ ID NO. 6, 7, and 8, or sequences thereof having GPRC5D binding affinity after addition, deletion, modification, and / or substitution of at least one amino acid.
[0098] In the above content of the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably not more than 40% of the total number of amino acids in the initial amino acid sequence, more preferably not more than 35%, more preferably 1-33%, more preferably 5-30%, more preferably 10-25%, more preferably 15-20%.
[0099] In certain embodiments of the present invention, the number of added, deleted, modified and / or substituted amino acids is usually 1, 2, 3, 4 or 5, preferably 1-3, more preferably 1-2, and most preferably 1.
[0100] In certain embodiments of the present invention, the anti-GPRC5D antibody is an anti-human GPRC5D antibody. The amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the anti-human GPRC5D antibody are shown in SEQ ID NO.1 and SEQ ID NO.5.
[0101] In certain embodiments of the present invention, the anti-GPRC5D antibody further comprises a heavy chain constant region and a light chain constant region. The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.9, and / or the amino acid sequence of the light chain constant region is shown in SEQ ID NO.10.
[0102] In certain embodiments of the present invention, the anti-GPRC5D antibody is a humanized antibody. The formed sequence is preferably an amino acid sequence with a homology of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. The antibody of the present invention can be a double-chain or single-chain antibody, and can preferably be a fully humanized antibody.
[0103] In certain embodiments of the present invention, the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO.5, the amino acid sequence of the heavy chain constant region is shown as SEQ ID NO.9, and the amino acid sequence of the light chain constant region is shown as SEQ ID NO.10.
[0104] In the anti-GPRC5D antibody provided by the present invention, the antibody is an IgG antibody. In certain embodiments of the present invention, the antibody is an IgG1 antibody. The present invention determines the cross-reactivity of the hybridoma supernatant with CHOK1 cells expressing human GPRC5D and blank CHOK1 by measuring the binding of the hybridoma supernatant with CHOK1 cells expressing human GPRC5D, and then uses flow cytometry to determine the binding of the hybridoma supernatant with CHOK1 cells expressing human GPRC5D, and uses positive clones to react only with CHOK1 cells expressing human GPRC5D to screen out candidate clones. The antibody is expected to be used for the treatment of tumors expressing GPRC5D.
[0105] Another aspect of the present invention provides a recombinant protein, which contains the aforementioned anti-GPRC5D antibody of the present invention and an optional tag sequence for facilitating expression and / or purification.
[0106] In certain embodiments of the present invention, the tag sequence includes a 6His tag.
[0107] In certain embodiments of the present invention, the recombinant protein (or polypeptide) includes a fusion protein.
[0108] In certain embodiments of the present invention, the recombinant protein is a monomer, a dimer, or a polymer.
[0109] In certain embodiments of the present invention, the recombinant protein further comprises an additional fusion element (or fusion polypeptide fragment) fused with the anti-GPRC5D antibody.
[0110] Another aspect of the present invention provides a CAR construct, wherein the scFv segment of the antigen binding region of the CAR construct is a binding region that specifically binds to GPRC5D, and the scFv segment contains the aforementioned anti-GPRC5D antibody. "CAR" or "chimeric antigen receptor" refers to a fusion protein comprising an extracellular domain capable of binding to an antigen, a transmembrane domain derived from a polypeptide different from the derived polypeptide of the extracellular domain, and at least one intracellular domain. "Chimeric antigen receptor" is sometimes also referred to as a "chimeric receptor", "T-body" or "chimeric immune receptor (CIR)". "Extracellular domain capable of binding to an antigen" refers to any oligopeptide or polypeptide that can bind to a specific antigen. "Intracellular domain" refers to any oligopeptide or polypeptide known to act in a cell as a domain that transmits signals to cause activation or inhibition of a biological process.
[0111] Another aspect of the present invention provides a recombinant immune cell, which expresses the exogenous aforementioned CAR construct. Recombinant immune cells generally refer to immune cells modified by genetic engineering methods so that they can more effectively recognize and attack specific pathogens or tumor cells. The immune cells can be NK cells or T cells.
[0112] Another aspect of the present invention provides an antibody conjugate, comprising the antibody and an effector molecule, wherein the antibody is coupled to the effector molecule, and preferably chemically coupled. The effector molecule is preferably a drug with therapeutic activity. In addition, the effector molecule may be one or more of a toxic protein, a chemotherapeutic drug, a small molecule drug, or a radionuclide.
[0113] The antibody of the present invention and the effector molecule can be coupled via a coupling agent. Examples of the coupling agent can be any one or more of a non-selective coupling agent, a coupling agent utilizing a carboxyl group, a peptide chain, and a coupling agent utilizing a disulfide bond. The non-selective coupling agent refers to a compound that forms a covalent bond between the effector molecule and the antibody, such as glutaraldehyde. The coupling agent utilizing a carboxyl group can be any one or more of a cis-aconitic anhydride coupling agent (such as cis-aconitic anhydride) and an acylhydrazone coupling agent (the coupling site is an acylhydrazone).
[0114] Certain residues on antibodies (such as Cys or Lys, etc.) are used to connect to a variety of functional groups, including imaging agents (such as chromophores and fluorescent groups), diagnostic agents (such as MRI contrast agents and radioisotopes), stabilizers (such as ethylene glycol polymers) and therapeutic agents. Antibodies can be coupled to functional agents to form antibody-functional agent conjugates. Functional agents (such as drugs, detection agents, stabilizers) are coupled (covalently linked) to antibodies. Functional agents can be directly or indirectly linked to antibodies through linkers.
[0115] Antibodies can be coupled to drugs to form antibody drug conjugates (ADCs). Typically, ADCs contain a linker between the drug and the antibody. The linker can be degradable or non-degradable. Degradable linkers are typically easily degraded in the intracellular environment, such as degradation of the linker at the target site, thereby releasing the drug from the antibody. Suitable degradable linkers include, for example, enzyme-degradable linkers, including peptidyl-containing linkers that can be degraded by intracellular proteases (such as lysosomal proteases or endosomal proteases), or sugar linkers, such as glucuronide-containing linkers that can be degraded by glucuronidase. Peptide linkers can include, for example, dipeptides, such as valine-citrulline, phenylalanine-lysine or valine-alanine. Other suitable degradable linkers include, for example, pH-sensitive linkers (such as linkers that hydrolyze at pH less than 5.5, such as hydrazone linkers) and linkers that degrade under reducing conditions (such as disulfide linkers). Non-degradable linkers typically release the drug under conditions where the antibody is hydrolyzed by proteases.
[0116] Prior to attachment to the antibody, the linker has an active reactive group capable of reacting with certain amino acid residues, and attachment is achieved through the active reactive group. Thiol-specific active reactive groups are preferred and include, for example, maleimide compounds, halogenated amides (e.g., iodinated, brominated or chlorinated); halogenated esters (e.g., iodinated, brominated or chlorinated); halogenated methyl ketones (e.g., iodinated, brominated or chlorinated), benzyl halides (e.g., iodinated, brominated or chlorinated); vinyl sulfones, pyridyl disulfides; mercury derivatives such as 3,6-di-(mercurymethyl)dioxane, and the counter ion is acetate, chloride or nitrate; and polymethylene dimethyl sulfide thiosulfonate. The linker may include, for example, maleimide attached to the antibody via thiosuccinimide.
[0117] The drug can be any cytotoxic, cytostatic or immunosuppressive drug. In certain embodiments, a linker connects the antibody and the drug, and the drug has a functional group that can form a bond with the linker. For example, the drug can have an amino, carboxyl, sulfhydryl, hydroxyl, or keto group that can form a bond with the linker. In the case where the drug is directly connected to the linker, the drug has a reactive group before being connected to the antibody.
[0118] Useful drug classes include, for example, anti-tubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, folic acid antagonists, antimetabolites, chemosensitizers, topoisomerase inhibitors, vinca alkaloids, etc. In the present invention, drug-linkers can be used to form ADCs in a simple step. In other embodiments, bifunctional linker compounds can be used to form ADCs in a two-step or multi-step method. For example, a cysteine residue reacts with a reactive portion of a linker in a first step, and in a subsequent step, a functional group on the linker reacts with a drug to form an ADC.
[0119] Typically, the functional groups on the linker are selected to react specifically with the appropriate reactive groups on the drug moiety. As a non-limiting example, azide-based moieties can be used to react specifically with reactive alkynyl groups on the drug moiety. The drug is covalently bound to the linker by a 1,3-dipolar cycloaddition between the azide and the alkynyl groups. Other useful functional groups include, for example, ketones and aldehydes (suitable for reaction with hydrazides and alkoxyamines), phosphines (suitable for reaction with azides); isocyanates and isothiocyanates (suitable for reaction with amines and alcohols); and activated esters, such as N-hydroxysuccinimide esters (suitable for reaction with amines and alcohols). These and other linking strategies, such as those described in Bioconjugation Technology, Second Edition (Elsevier), are well known to those skilled in the art. Those skilled in the art will appreciate that for selective reaction of the drug moiety and the linker, when a complementary pair of reactive functional groups is selected, each member of the complementary pair can be used for both the linker and the drug.
[0120] Another aspect of the present invention provides an isolated polynucleotide encoding the aforementioned anti-GPRC5D antibody, the aforementioned recombinant protein, or the aforementioned CAR construct. The isolated polynucleotide full-length sequence or its fragment of the present application can usually be obtained by PCR amplification, recombination or artificial synthesis.
[0121] Another aspect of the present invention provides an expression vector comprising the aforementioned isolated polynucleotide. "Vector" refers to a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. The vector in the present invention generally refers to various commercially available expression vectors well known in the art, such as bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors.
[0122] Another aspect of the present invention provides a cell, comprising the aforementioned expression vector or the aforementioned isolated polynucleotide integrated into the genome. The cell is obtained by transfecting the expression vector into a host cell. "Host cell" means that any cell suitable for expression by the expression vector can be used as a host cell, for example, the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
[0123] Another aspect of the present invention provides a method for preparing the aforementioned anti-GPRC5D antibody, which comprises culturing the aforementioned cells and isolating the anti-GPRC5D antibody from the cell culture.
[0124] Another aspect of the present invention provides a use of an active ingredient, wherein the active ingredient is selected from one or more of the following: the anti-GPRC5D antibody as described above in the present invention, the recombinant protein as described above in the present invention, the CAR construct as described above in the present invention, the immune cell as described above in the present invention, and the antibody conjugate as described above in the present invention, and the active ingredient is used to prepare a reagent or kit for detecting GPRC5D protein, and / or to prepare a drug or preparation for preventing and / or treating GPRC5D-related diseases.
[0125] Another aspect of the present invention provides a pharmaceutical composition comprising the aforementioned active ingredient and a pharmaceutically acceptable carrier and / or excipient.
[0126] "Pharmaceutically acceptable carriers or excipients" should be compatible with lysosomal regulatory factors, that is, they can be mixed with them without significantly reducing the effect of the drug under normal circumstances. Specific examples of some substances that can be used as pharmaceutically acceptable carriers or excipients are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethyl cellulose and methyl cellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavorings; tableting agents, stabilizers, antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffer, etc. These materials are used as needed to aid in the stability of the formulation or to help increase the activity or its bioavailability or to produce an acceptable taste or flavor in the case of oral administration.
[0127] The drug provided by the present invention can be adapted to any form of administration, which can be oral or parenteral administration, for example, it can be pulmonary, nasal, rectal and / or intravenous injection, more specifically, it can be intradermal, subcutaneous, intramuscular, intra-articular, intraperitoneal, pulmonary, oral, sublingual, nasal, transdermal, vaginal, oral or parenteral administration.
[0128] Those skilled in the art can select a suitable preparation form according to the mode of administration. For example, the preparation form suitable for oral administration may include but is not limited to pills, tablets, chewables, capsules, granules, drops or syrups, etc. For another example, the preparation form suitable for parenteral administration may include but is not limited to solutions, suspensions, reconstituted dry preparations or sprays, etc. For another example, it may be a suppository suitable for rectal administration. For another example, the pharmaceutical composition of the present invention may be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 microgram / kg body weight to about 5 mg / kg body weight per day. In addition, the polypeptide of the present invention may also be used together with other therapeutic agents.
[0129] The anti-GPRC5D antibody of the present invention can also be expressed in cells by nucleotide sequences for cell therapy, for example, the anti-GPRC5D antibody is used for chimeric antigen receptor T cell immunotherapy (CAR-T) and the like.
[0130] The pharmaceutical composition of the present invention can be directly used to bind to GPRC5D protein molecules, kill cells expressing GPRC5D, and prevent and treat GPRC5D-related diseases. In addition, other therapeutic agents can also be used simultaneously.
[0131] In the uses provided in the present application, the killing is mediated by ADCC.
[0132] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells that specifically bind to antibodies or derivatives thereof that contain an Fc region, and the specific binding is usually through the protein portion of the N-terminus of the Fc region. Suitable assays for measuring ADCC are well known in the art (see, for example, PCT Publication No. WO 2006 / 082515 or PCT Publication No. WO 2012 / 130831). The antibodies of the present application can induce antibody-dependent cytotoxicity of effector cells to achieve killing of tumor cells expressing GPRC5D.
[0133] In the use provided by the present invention, the tumor expressing GPRC5D is selected from adrenal cortical carcinoma, bladder urothelial carcinoma, breast cancer, cervical squamous cell carcinoma, endocervical adenocarcinoma, bile duct cancer, colon adenocarcinoma, lymphoid tumors, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, acute myeloid leukemia, low-grade glioma of the brain, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelial carcinoma, ovarian cancer, pancreatic cancer, chromaffin Preferably, the tumor expressing GPRC5D is selected from lymphoma or myeloma; more preferably, the myeloma is multiple myeloma.
[0134] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned monoclonal antibody (or its conjugate) of the present invention and a pharmaceutically acceptable carrier or excipient.
[0135] When using a pharmaceutical composition, a safe and effective amount of the pharmaceutical composition is administered to a mammal, wherein the safe and effective amount is usually at least about 10 micrograms / kg body weight, and in most cases does not exceed about 50 milligrams / kg body weight, preferably the dose is about 10 micrograms / kg body weight to about 20 milligrams / kg body weight. Of course, the specific dose should also take into account factors such as the route of administration and the patient's health status, which are all within the skill of a skilled physician.
[0136] Another aspect of the present invention provides a detection use, such as for detecting a sample, thereby providing diagnostic information.
[0137] In the present invention, the sample (specimen) used includes cells, tissue samples and biopsy specimens. The term "biopsy" used in the present invention should include all types of biopsies known to those skilled in the art. Therefore, the biopsy used in the present invention can include, for example, tissue samples prepared by endoscopic methods or puncture or needle biopsy of an organ.
[0138] Samples used in the present invention include fixed or preserved cell or tissue samples.
[0139] Another aspect of the present invention provides a method for treating a tumor expressing GPRC5D, comprising administering an effective dose of the aforementioned anti-GPRC5D antibody, the aforementioned isolated polynucleotide, the aforementioned expression vector or the aforementioned cell to a subject.
[0140] In the treatment methods provided in the present application, the subjects are mammals, such as rodents, artiodactyls, perissodactyls, lagomorphs, primates, etc. Primates are, for example, monkeys, apes or Homo sapiens. An effective dose generally refers to an amount that can achieve the effect of treating tumors after an appropriate administration period.
[0141] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0142] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0143] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention. Example
[0144] Hereinafter, the present invention will be described in more detail with reference to examples. However, it will be apparent to those skilled in the art that these examples are provided only to illustrate the present invention and should not be construed as limiting the scope of the present invention.
[0145] In order to produce antibodies against human GPRC5D, LNP-encapsulated GPRC5D mRNA was used as an antigen to immunize 6-8 week old Balb / c female mice. The mice were immunized by standard mRNA immunization procedures. After 5 times, the spleen of the mice was taken and fused with SP2 / 0 cells using the BTX electrofusion system to produce hybridomas. The cross-reactivity of the hybridoma supernatant with CHOK1 cells expressing human GPRC5D and blank CHOK1 was determined using a Cell-based ELISA format. Flow cytometry was then used to determine the binding of the hybridoma supernatant to CHOK1 cells expressing human GPRC5D. Positive clones react only to CHOK1 cells expressing human GPRC5D. The selected candidate clones were used to retrieve the relevant antibody sequences by specific gene amplification technology.
[0146] A total of 8 antibody heavy chain variable regions (VH) and light chain variable regions (VL) obtained by hybridoma sequencing were constructed on phage containing hIgG1 and kappa chain constant regions, co-transfected into freestyle 293F cells, and the supernatant was collected after 3-7 days of culture. Purification with protein A column obtained the corresponding antibody protein. The VH and VL of the sequence G6DXd with good detection results in the hybridoma were selected for humanization to obtain the humanized antibody G6DXdC. The variable region sequence is as follows Figure 1 As shown in the figure, the underlined area is CDRs (IMGT definition), and the corresponding CDR sequences are as follows Figure 2 The constant region amino acid sequence is shown in Figure 3 shown.
[0147] The full-length GPRC5D expression vector was constructed and transfected into CHOK1 cells. Hygromycin screening was performed to obtain mixed clones. Then, the monoclonal cell line stably expressing CHOK1-hGPRC5D was obtained by limiting dilution method. The binding ability of anti-GPRC5D antibody to CHOK1-hGPRC5D cells was detected by flow cytometry. Specifically, 3×10 5 CHOK1-hGPRC5D cells were added with gradient dilutions of GPRC5D antibody protein, incubated for 1 hour, washed once with PBS, added with Anti-hFc-APC (purchased from Jackson Immunology), washed once with PBS, and then tested on a flow cytometer. The EC50 results of cell affinity detected by flow cytometry are shown in Figure 4 The reference antibody Talquetamab here is a monoclonal antibody version of GPRC5D (the variable region of GPRC5D in the Talquetamab bispecific antibody is recombined with the constant region of Human IgG1 into a monoclonal antibody). The flow cytometry EC50 results showed that G6DXdC has a higher binding ability to cells than Talquetamab.
[0148] This example mainly demonstrates the internalization effect of anti-GPRC5D antibody on GPRC5D positive cells. Specifically, iQue® Human Antibody Internalization Reagent (Sartorius, CAT NO: 90564) was used to couple the internalization reagent to the antibody and then incubated with CHOK1-hGPRC5D cells for 1h, 2h, 3h, and 4h, respectively, and then the positive rate was detected by flow cytometry. The measured positive rate represents the internalization efficiency of the antibody, and the highest positive rate represents the highest internalization efficiency.
[0149] Results Figure 5 From the maximum internalization rate, it can be seen that the maximum internalization rate of G6DXdC is lower than that of Talquetamab.
[0150] The method for detecting the ADCC effect of antibodies in this experiment is the reporter gene method. Jurkat ADCC Res cell line (Novoprotein, Cat No. XCC35) was used as the ADCC response cell line for subsequent antibody detection. The higher the response value, the higher the ADCC effect.
[0151] 1.6×10 6 25 μL XCC35 cells (40,000 cells / well) were added to a 96-well plate at a density of 0.4×10 6 25 μL CHOK1-hGPRC5D cells (10,000 cells / well) were added to a 96-well plate at a density of 100 μg / mL, incubated at 37°C overnight, and 50 μL of gradient diluted anti-GPRC5D antibody was added to the 96-well plate, starting from 20 μg / mL, and diluted 5-fold in 7 gradients; after overnight incubation, the cells were lysed and luciferase substrate (Promega, Cat. No. E1501) was added to detect luciferase activity. Results are shown in Figure 6 The ADCC effect of G6DXdC is stronger than that of Talquetamab.
[0152] In order to verify the specificity of the anti-GPRC5D antibody, a CHOK1-hGPRC5A cell line stably expressing GPRC5A (UniProt Q8NFJ5) was constructed, and its nonspecific binding to the antibody was detected by flow cytometry. The results are shown in Figure 7 The tested antibodies G6DXdC and Talquetamab had no non-specific binding to GPRC5A-positive cells.
[0153] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.
Claims
1. An anti-GPRC5D antibody, characterized in that The anti-GPRC5D antibody comprises a heavy chain and a light chain, and the heavy chain variable region of the heavy chain and the light chain variable region of the light chain have the following characteristics: 1) The heavy chain variable region includes CDR1, and the CDR1 has the amino acid sequence shown in SEQ ID NO.2; 2) The heavy chain variable region includes CDR2, and the CDR2 has the amino acid sequence shown in SEQ ID NO.3; 3) The heavy chain variable region includes CDR3, and the CDR3 has the amino acid sequence shown in SEQ ID NO.4; 4) The light chain variable region includes CDR1, and the CDR1 has the amino acid sequence shown in SEQ ID NO.6; 5) The light chain variable region includes CDR2, wherein the CDR2 has an amino acid sequence as shown in SEQ ID NO.7, and the amino acid sequence of the CDR2 is KVS; 6) The light chain variable region includes CDR3, and the CDR3 has the amino acid sequence shown in SEQ ID NO.
8.
2. The anti-GPRC5D antibody according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1 and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
5.
3. The anti-GPRC5D antibody according to claim 2, characterized in that The anti-GPRC5D antibody further comprises a heavy chain constant region and a light chain constant region.
4. The anti-GPRC5D antibody according to claim 3, characterized in that The heavy chain constant region is an IgG1 heavy chain constant region, and / or the light chain constant region is a Kappa light chain constant region.
5. The anti-GPRC5D antibody according to claim 4, characterized in that The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.9 and the amino acid sequence of the light chain constant region is shown in SEQ ID NO.
10.
6. The anti-GPRC5D antibody according to claim 1, characterized in that The anti-GPRC5D antibody is a humanized antibody.
7. A recombinant protein, characterized in that The recombinant protein consists of the anti-GPRC5D antibody according to any one of claims 1 to 6 and a tag sequence that assists expression and / or purification.
8. A CAR construct, characterized in that: The extracellular domain of the CAR construct contains the scFv of the anti-GPRC5D antibody according to claim 1 or claim 2.
9. A recombinant immune cell, characterized in that: The immune cells express an exogenous CAR construct as described in claim 8.
10. The immune cell according to claim 9, characterized in that The immune cells are selected from one or more of the following: NK cells, T cells.
11. An antibody conjugate, characterized in that: The antibody conjugate contains an antibody portion and a conjugated portion conjugated to the antibody portion, wherein the antibody portion is selected from one or more of the following: the anti-GPRC5D antibody according to any one of claims 1 to 6, and the recombinant protein according to claim 7.
12. The antibody conjugate according to claim 11, characterized in that The coupling part is selected from one or more of the following: a detectable label, a toxin, a cytokine, a radionuclide, and an enzyme.
13. A use of an active ingredient, characterized in that: The active ingredient is selected from one or more of the following: the anti-GPRC5D antibody according to any one of claims 1 to 6, the recombinant protein according to claim 7, the CAR construct according to claim 8, the immune cell according to claim 9, and the antibody conjugate according to claim 11, and the active ingredient is used for: 1) Prepare reagents or kits for detecting GPRC5D protein; 2) Preparation of drugs or preparations for preventing and / or treating multiple myeloma with overexpression of GPRC5D.
14. A pharmaceutical composition, characterized in that The pharmaceutical composition contains the anti-GPRC5D antibody according to any one of claims 1 to 6, the recombinant protein according to claim 7, the CAR construct according to claim 8, the immune cell according to claim 9 and / or the antibody conjugate according to claim 11, and a pharmaceutically acceptable carrier and / or excipient.
15. An isolated polynucleotide, characterized in that Encoding the anti-GPRC5D antibody according to any one of claims 1 to 6, the recombinant protein according to claim 7, or the CAR construct according to claim 8.
16. An expression vector, characterized in that: Contains the isolated polynucleotide as claimed in claim 15.
17. A cell, characterized in that Contains the expression vector as claimed in claim 16 or has the isolated polynucleotide as claimed in claim 15 integrated into its genome.
